Promoting Engagement in the Drug Resistant TB-HIV Care Continuum in South Africa PRAXIS Study

NACompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

April 29, 2018

Primary Completion Date

September 28, 2021

Study Completion Date

December 5, 2022

Conditions
Adherence, Patient
Interventions
DEVICE

Wisepill device

"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."

Trial Locations (1)

Unknown

King Dinuzulu Hospital, Durban

All Listed Sponsors
collaborator

Columbia University

OTHER

lead

Centre for the AIDS Programme of Research in South Africa

NETWORK

NCT04032730 - Promoting Engagement in the Drug Resistant TB-HIV Care Continuum in South Africa PRAXIS Study | Biotech Hunter | Biotech Hunter